Dr. Lal PathLabs Declares Interim Dividend, Approves Investment

Dr. Lal PathLabs Ltd announced its unaudited financial results for the quarter and half-year ended September 30, 2026. The Board of Directors declared a second interim dividend of INR 5 per equity share for FY2026-27, with a record date of November 11, 2026. Additionally, the company approved a further investment of up to INR 49.5 Crores in its wholly-owned subsidiary, Dr. Lal PathLabs FZCO (LPL Dubai), to support its business and operational needs, including further investment in its subsidiary Sunshine Healthcare Limited (SHL), Ghana. The Board also approved the appointment of Ms. Vasuta Agarwal as an Additional Director, designated as a Non-Executive Independent Director, for a term of three years, subject to shareholder approval.